The effects of anti-NOTCH1 OMP-52M51 have been evaluated in T-ALL cell lines and primary samples [13] and are enhanced when combined with dexamethasone, the main drug of the combined therapy plan used in T-ALL treatment. The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.